Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cyclacel Pharmaceuticals, Inc.
Vall d'Hebron University Hospital and Cyclacel to Initiate Phase 1 Combination Study of Seliciclib and Tarceva in Advanced Cancers
June 10th, 2008
Vall d'Hebron University Hospital and Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced a collaboration to conduct a Phase 1 study of investigational therapy seliciclib in combination with erlotinib (Tarceva(R)) in patients with advanced solid tumors including non-small cell lung cancer (NSCLC). Seliciclib, Cyclacel's orally available cyclin dependent kinase (CDK) inhibitor, has shown encouraging anti-cancer activity in several Phase 1 and Phase 2 studies. Seliciclib is currently being tested as a single agent in the treatment of patients with non-small cell lung cancer in the Phase 2b APPRAISE trial and in a Phase 2 study in patients with nasopharyngeal cancer....
Source: Cancer Weekly (2008-06-10)
|
